OrbiMed Launches $307 Million Fund to Focus on Israeli Life Science Firms

Published: May 24, 2016

Israel flagOrbiMed has launched a $307 million venture capital fund five years after its inagural $202 million fund investing in biotech, diagnostic and medical device and digital health companies.

OrbiMed Israel Partners I invested in 28 companies. Merck acquired portfolio company cCam Biotherapeutics in August, marking its first big exit from the fund.

In a phone interview with OrbiMed Advisors, General Partner Carter Neild said OrbiMed Israel Partners II would also make around 20 investments, 50 percent of them in biotech companies with the rest split between diagnostics, digital health, and medical devices.

Back to news